[go: up one dir, main page]

Xiao et al., 2024 - Google Patents

Association of synaptic density and cognitive performance in temporal lobe epilepsy: Humans and animals PET imaging study with [18F] SynVesT‐1

Xiao et al., 2024

View PDF @Full View
Document ID
5021912785165614144
Author
Xiao L
Xiang S
Chen C
Zhu H
Zhou M
Tang Y
Feng L
Hu S
Publication year
Publication venue
Psychiatry and Clinical Neurosciences

External Links

Snippet

Aim Cognitive impairment is a common comorbidity in individuals with temporal lobe epilepsy (TLE), yet the underlying mechanisms remain unknown. This study explored the putative association between in vivo synaptic loss and cognitive outcomes in TLE patients …
Continue reading at onlinelibrary.wiley.com (PDF) (other versions)

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082Supracellular entities, e.g. tissue, organisms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2835Movement disorders, e.g. Parkinson, Huntington, Tourette
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/30Psychoses; Psychiatry
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue

Similar Documents

Publication Publication Date Title
Huang et al. Glymphatic system dysfunction predicts amyloid deposition, neurodegeneration, and clinical progression in Alzheimer's disease
Erritzoe et al. Brain serotonin release is reduced in patients with depression: a [11C] Cimbi-36 positron emission tomography study with a d-amphetamine challenge
Wilson et al. Mitochondrial complex 1, sigma 1, and synaptic vesicle 2A in early drug‐naive Parkinson's disease
Sundal et al. MRI characteristics and scoring in HDLS due to CSF1R gene mutations
Brabazon et al. Intranasal insulin treatment of an experimental model of moderate traumatic brain injury
Hu et al. Neurofilament light chain plasma concentration predicts neurodegeneration and clinical progression in nondemented elderly adults
Nordanskog et al. Hippocampal volume in relation to clinical and cognitive outcome after electroconvulsive therapy in depression
Gildengers et al. Longer lithium exposure is associated with better white matter integrity in older adults with bipolar disorder
Pettorruso et al. Striatal presynaptic dopaminergic dysfunction in gambling disorder: A 123I‐FP‐CIT SPECT study
Tang et al. Spatial learning and memory impairments are associated with increased neuronal activity in 5XFAD mouse as measured by manganese-enhanced magnetic resonance imaging
Vegting et al. The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies
Sydnor et al. Studying pre-treatment and ketamine-induced changes in white matter microstructure in the context of ketamine’s antidepressant effects
Xiao et al. Association of synaptic density and cognitive performance in temporal lobe epilepsy: Humans and animals PET imaging study with [18F] SynVesT‐1
Sihvonen et al. Right hemispheric structural connectivity and poststroke language recovery
Trigiani et al. A functional cerebral endothelium is necessary to protect against cognitive decline
Duara et al. The basis for disease-modifying treatments for Alzheimer's disease: the Sixth Annual Mild Cognitive Impairment Symposium
Tiger et al. [11C] raclopride positron emission tomography study of dopamine‐D2/3 receptor binding in patients with severe major depressive episodes before and after electroconvulsive therapy and compared to control subjects
Beglopoulos et al. Early detection of cryptic memory and glucose uptake deficits in pre-pathological APP mice
Onos et al. Assessment of neurovascular uncoupling: APOE status is a key driver of early metabolic and vascular dysfunction
Dai et al. Expansion of clinical and genetic spectrum of DDX3X neurodevelopmental disorder in 23 Chinese patients
Ponirakis et al. Corneal nerve loss predicts dementia in patients with mild cognitive impairment
Fatima et al. Breakthroughs in Alzheimer’s research: a path to a more promising future?
Suchy‐Dicey et al. Volume atrophy in medial temporal cortex and verbal memory scores in American Indians: Data from the Strong Heart Study
Boecker‐Schlier et al. Association between pubertal stage at first drink and neural reward processing in early adulthood
Bäckström et al. PITX3 genotype and risk of dementia in Parkinson's disease: A population-based study